Log in
NASDAQ:ALBO

Albireo Pharma Stock Forecast, Price & News

$38.90
-0.15 (-0.38 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$38.55
Now: $38.90
$39.58
50-Day Range
$24.18
MA: $29.53
$41.61
52-Week Range
$11.26
Now: $38.90
$49.00
Volume329,842 shs
Average Volume193,276 shs
Market Capitalization$583.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Read More
Albireo Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.20 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.64 million
Book Value$7.34 per share

Profitability

Net Income$-62,720,000.00
Net Margins-722.91%

Miscellaneous

Employees39
Market Cap$583.15 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$38.90
-0.15 (-0.38 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

How has Albireo Pharma's stock price been impacted by COVID-19?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 120.6% and is now trading at $38.90.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Albireo Pharma?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Albireo Pharma
.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Albireo Pharma
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma Inc (NASDAQ:ALBO) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, beating analysts' consensus estimates of ($1.65) by $0.27. Albireo Pharma had a negative return on equity of 82.06% and a negative net margin of 722.91%.
View Albireo Pharma's earnings history
.

What price target have analysts set for ALBO?

8 analysts have issued twelve-month target prices for Albireo Pharma's stock. Their forecasts range from $52.00 to $81.00. On average, they anticipate Albireo Pharma's stock price to reach $67.71 in the next year. This suggests a possible upside of 74.1% from the stock's current price.
View analysts' price targets for Albireo Pharma
.

Are investors shorting Albireo Pharma?

Albireo Pharma saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,440,000 shares, an increase of 34.6% from the August 15th total of 1,070,000 shares. Based on an average daily volume of 316,400 shares, the short-interest ratio is presently 4.6 days.
View Albireo Pharma's Short Interest
.

Who are some of Albireo Pharma's key competitors?

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), GW Pharmaceuticals PLC- (GWPH), Palatin Technologies (PTN), Agenus (AGEN), Novavax (NVAX) and AT&T (T).

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 56)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 67)
  • Dr. Paresh N. Soni, Consultant (Age 59)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Mr. Simon Harford, CFO & Treasurer

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (6.38%), Chicago Capital LLC (3.35%), Artal Group S.A. (3.34%), FMR LLC (1.57%), FMR LLC (1.57%) and Prosight Management LP (1.33%). Company insiders that own Albireo Pharma stock include Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends for Albireo Pharma
.

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Prosight Management LP, Artal Group S.A., FMR LLC, FMR LLC, ArrowMark Colorado Holdings LLC, Alps Advisors Inc., and Bank of America Corp DE. Company insiders that have sold Albireo Pharma company stock in the last year include Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma
.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Driehaus Capital Management LLC, Man Group plc, Nuveen Asset Management LLC, M&T Bank Corp, Bank of New York Mellon Corp, California Public Employees Retirement System, and Chicago Capital LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, Perceptive Advisors Llc, and Ronald Harold Wilfred Cooper.
View insider buying and selling activity for Albireo Pharma
.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $38.90.

How big of a company is Albireo Pharma?

Albireo Pharma has a market capitalization of $583.15 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.